Point-of-Care Testing After the COVID-19 Demand Correction | Diagnostics Market Intelligence

Description

List of Tables

The point-of-care testing industry spent three years as the center of the diagnostics world and one year learning what that was worth. The correction was brutal and instructive: Cue Health, briefly valued in the billions on connected home molecular testing, went through Chapter 7; LumiraDx sold its platform assets to Roche after restructuring; antigen-test suppliers wrote down capacity; and investors re-rated the entire category from pandemic multiples to clinical reality. The question the correction left behind is not whether point-of-care testing survives - physicians have always valued fast answers - but which business models, menus, and channels generate durable demand when no emergency is filling the instruments.

Japan reframes that question in useful ways. Its primary care is clinic-dense and physician-owned, its patients expect same-visit answers, its NHI schedule reimburses a defined menu of rapid tests at modest prices, and its pandemic-era adoption of antigen testing was broad but clinic-mediated rather than home-led. The structures that made American home-testing economics fragile - self-pay, employer contracts, consumer marketing - barely exist in Japan, which means the post-COVID reckoning looks different: less collapse, more a slow audit of which instruments earn their bench space between influenza seasons.

This report sorts the survivors from the stories. It reconstructs the boom-and-correction cycle and its emblematic failures, profiles the companies whose models endured and why, and maps Japan's demand structure in detail: clinic economics, the reimbursed rapid-test menu, pediatric and elderly-care applications, and the pharmacy and home channels that remain mostly promise. Menu-strategy chapters assess where growth can come from - multiplex respiratory panels, STI decentralization, chronic-disease monitoring - and what each would require from reimbursement and distribution. The final chapters examine preparedness policy, consolidation, and the entry openings the correction created.

The report serves POCT companies calibrating post-pandemic strategy, investors distinguishing durable models from residual hype, distributors rationalizing portfolios, and Japan entrants evaluating a channel that punishes the wrong business model quickly.

Scope and Coverage: The report covers the point-of-care testing industry after the COVID-19 demand correction: company outcomes, surviving business models, menu and channel strategy, and Japan's demand structure. Comparative coverage includes the United States, Europe, and China.

Report Highlights:

Case anatomies of the correction's emblematic failures and asset sales
Profile of surviving business models and their demand anchors
Japan's clinic-based demand structure and reimbursed rapid-test menu
Menu expansion analysis: respiratory panels, STI, and chronic-disease testing
Channel assessment across clinics, hospitals, pharmacies, and home
Entry openings created by the correction and consolidation landscape

Product Code: JPH-054

Table of Content

1. Executive Summary

2. Point-of-Care Testing After the COVID-19 Demand Correction: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Cue Health (US) - Chapter 7 bankruptcy (2024) as the emblem of the COVID POCT demand collapse. Abbott (US) - BinaxNOW and ID NOW transitioned from pandemic volume to routine respiratory testing. Roche (CH) - acquired LumiraDx platform assets (2024) for point-of-care expansion. Danaher/Cepheid (US) - GeneXpert sustained by TB and STI non-COVID menu. LumiraDx (UK) - restructuring and asset sale to Roche after the demand correction. Wondfo (CN) - rapid antigen and POCT portfolio redirected to domestic and export routine testing. QuidelOrtho (US) - Sofia and QuickVue respiratory testing franchises. Kyorin (JP) - GeneSoC molecular POCT for Japan's clinic market. Sekisui Medical (JP) - rapid antigen tests for influenza and COVID in Japanese clinics. Otsuka (JP) - diagnostic distribution and clinic-channel presence. Orient Gene (CN) - rapid-test manufacturing redirected after the pandemic period.

Product Code: JPH-054

List of Tables

Table 1. COVID-19 POCT demand cycle: expansion and correction timeline
Table 2. Cue Health business model and Chapter 7 anatomy
Table 3. LumiraDx restructuring and asset sale to Roche
Table 4. Abbott BinaxNOW and ID NOW demand transition
Table 5. Antigen test supplier retrenchment after the pandemic
Table 6. Inventory and capacity overhang following the correction
Table 7. Investor re-rating of POCT companies
Table 8. Cepheid GeneXpert: non-COVID menu anchors
Table 9. Roche POCT portfolio strategy after the LumiraDx acquisition
Table 10. Abbott Rapid Diagnostics franchise structure
Table 11. QuidelOrtho post-merger POCT position
Table 12. Sekisui Medical and domestic Japanese POCT suppliers
Table 13. Fujirebio and Sysmex POCT-adjacent positions
Table 14. Durable demand segments: respiratory, streptococcus, influenza
Table 15. Connectivity-enabled POCT business models
Table 16. Japan clinic density and primary care testing culture
Table 17. NHI reimbursement of rapid tests in Japan
Table 18. Influenza and COVID antigen testing practice in clinics
Table 19. Clinic laboratory versus in-office testing split
Table 20. Pediatric testing patterns in Japanese primary care
Table 21. Elderly care facility testing applications
Table 22. Pharmacy testing regulations and pilot programs
Table 23. Home testing market status in Japan
Table 24. Post-COVID menu expansion frameworks
Table 25. Multiplex respiratory panels in decentralized settings
Table 26. STI testing expansion in clinics
Table 27. Cardiac and critical-care POCT segments
Table 28. HbA1c and chronic disease POCT
Table 29. Coagulation and INR POCT
Table 30. Urinalysis and UTI POCT
Table 31. Veterinary and adjacent segment spillover
Table 32. Instrument placement economics
Table 33. Reagent rental and cost-per-test models
Table 34. Reimbursement rate formation for rapid tests
Table 35. Clinic budget impact of POCT adoption
Table 36. Wholesale and distribution margin structure
Table 37. Service and maintenance cost frameworks
Table 38. Break-even frameworks for new POCT entrants
Table 39. Consolidation and M&A activity in POCT
Table 40. Pandemic preparedness stockpiling policy
Table 41. Rapid diagnostic development mission programs
Table 42. AMR as the next POCT demand driver
Table 43. Home and self-testing channel development
Table 44. Digital health integration of POCT results
Table 45. Regulatory watchlist for POCT in Japan
Table 46. Entrant opportunity map
Table 47. Failure mode analysis for POCT startups
Table 48. Adoption scenario framework
Table 49. Report methodology and evidence sources
Table 50. Workplace and employer-based POCT program structures

List of Figures

Figure 1. POCT demand cycle timeline
Figure 2. Cue Health failure anatomy
Figure 3. LumiraDx restructuring and asset flow
Figure 4. Abbott respiratory franchise transition map
Figure 5. Antigen supplier retrenchment map
Figure 6. Capacity overhang schematic
Figure 7. Investor re-rating timeline
Figure 8. GeneXpert menu anchor structure
Figure 9. Roche POCT portfolio map post-acquisition
Figure 10. Abbott Rapid Diagnostics structure
Figure 11. QuidelOrtho positioning map
Figure 12. Domestic Japanese supplier landscape
Figure 13. Fujirebio and Sysmex adjacent position map
Figure 14. Durable demand segment map
Figure 15. Connectivity business model schematic
Figure 16. Japan clinic density map
Figure 17. NHI rapid test menu structure
Figure 18. Clinic antigen testing workflow
Figure 19. In-office versus laboratory testing split framework
Figure 20. Pediatric testing pattern map
Figure 21. Elderly care facility testing pathway
Figure 22. Pharmacy testing regulatory map
Figure 23. Home testing market structure
Figure 24. Menu expansion framework
Figure 25. Multiplex respiratory panel pathway
Figure 26. STI clinic expansion map
Figure 27. Cardiac POCT segment map
Figure 28. Chronic disease POCT pathway
Figure 29. Coagulation POCT segment map
Figure 30. Urinalysis POCT segment map
Figure 31. Veterinary spillover map
Figure 32. Instrument placement economics model
Figure 33. Reagent rental model structure
Figure 34. Reimbursement rate formation flow
Figure 35. Clinic budget impact model
Figure 36. Distribution margin structure map
Figure 37. Service cost framework
Figure 38. Entrant break-even framework
Figure 39. POCT consolidation map
Figure 40. Preparedness stockpiling policy structure
Figure 41. Rapid development mission program map
Figure 42. AMR demand driver pathway
Figure 43. Home channel development map
Figure 44. Digital integration architecture for POCT
Figure 45. Regulatory watchlist timeline
Figure 46. Entrant opportunity map
Figure 47. Failure mode taxonomy for POCT startups
Figure 48. Adoption scenario tree
Figure 49. Report methodology schematic
Figure 50. Workplace POCT program structure map

Point-of-Care Testing After the COVID-19 Demand Correction | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Point-of-Care Testing After the COVID-19 Demand Correction: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures